• home
• research
• publications

As a medical oncologist treating patients with gastrointestinal malignancies, I encounter the need for new treatment approaches on a daily basis. The medical community has had a long-term interest in liver-directed therapies for colon cancer with liver metastasis. My ongoing phase II clinical trial using drug-eluting irinotecan beads tests a novel modality of treatment for unresectable, liver-predominant, metastatic colon cancer. There is also increasing interest in the role of Aurora kinase A as a contributing oncogene in the tumorigenesis of colon cancer. I am collaborating with other investigators at Fox Chase Cancer Center  to study the prognostic significance of increased Aurora A gene copy number in metastatic colon cancer.

I am also interested in studying the treatment and outcomes of elderly oncology patients. Treatment of this patient population is very challenging, and requires special attention and consideration. Limited tools are available to help the oncologist in identifying those patients who are more likely to suffer significant toxicity with chemotherapy. In an attempt to identify useful biologic markers that can help oncologists, I am studying the correlation between telomere length and chemotherapy tolerance among elderly oncology patients.

1. Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Seminars in Oncology Jan 2011 - in press.
2. Dotan E, Cohen R. The ongoing roll-out of aurora kinase inhibitors in cancer treatment. Drugs of the Future 2010 – in press
3. Dotan E, Goldstein LJ. Optimizing chemotherapy regimens for patients with early-stage breast cancer. Clin Breast Cancer. 2010;10 Suppl 1:E8-15. PubMed
4. Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. P T. 2010 Mar;35(3):148-57. PubMed
5. Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating tumor cells: evolving evidence and future challenges. Oncologist. 2009 Nov;14(11):1070-82. Epub 2009 Nov 6. PubMed